152 related articles for article (PubMed ID: 38880199)
21. Spesolimab in the Management of Generalized Pustular Psoriasis With Concurrent Bullous Pemphigoid and Psoriasis.
Teshima R; Saito-Sasaki N; Hitaka T; Sawada Y
Cureus; 2024 May; 16(5):e60331. PubMed ID: 38883056
[TBL] [Abstract][Full Text] [Related]
22. Spesolimab: A Novel Treatment for Pustular Psoriasis.
Ratnarajah K; Jfri A; Litvinov IV; Netchiporouk E
J Cutan Med Surg; 2020; 24(2):199-200. PubMed ID: 32208020
[No Abstract] [Full Text] [Related]
23. Exploring the Clinical Assessment, Guidelines, and Options for the Treatment of Generalized Pustular Psoriasis [Podcast].
Song EJ; Liu C
Clin Cosmet Investig Dermatol; 2023; 16():2911-2917. PubMed ID: 37915421
[TBL] [Abstract][Full Text] [Related]
24. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
Menter A; Van Voorhees AS; Hsu S
Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
[TBL] [Abstract][Full Text] [Related]
25. Spesolimab: First Approval.
Blair HA
Drugs; 2022 Nov; 82(17):1681-1686. PubMed ID: 36418672
[TBL] [Abstract][Full Text] [Related]
26. Spesolimab for the Treatment of Generalized Pustular Psoriasis.
Bernardo D; Thaçi D; Torres T
Drugs; 2024 Jan; 84(1):45-58. PubMed ID: 38114719
[TBL] [Abstract][Full Text] [Related]
27. Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors.
Maçães CO; Lé AM; Torres T
J Dermatolog Treat; 2022 Nov; 33(7):2911-2918. PubMed ID: 35695278
[TBL] [Abstract][Full Text] [Related]
28. [Remission of recalcitrant generalized pustular psoriasis under interleukin-36 receptor inhibitor spesolimab].
Müller VL; Kreuter A
Dermatologie (Heidelb); 2023 May; 74(5):356-359. PubMed ID: 36943426
[TBL] [Abstract][Full Text] [Related]
29. Autoinflammatory process in the pathogenesis of generalized pustular psoriasis and perspectives of its targeted therapy.
Javor J; Buc M; Bucová M
Epidemiol Mikrobiol Imunol; 2021; 70(3):199-207. PubMed ID: 34641694
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Morita A; Strober B; Burden AD; Choon SE; Anadkat MJ; Marrakchi S; Tsai TF; Gordon KB; Thaçi D; Zheng M; Hu N; Haeufel T; Thoma C; Lebwohl MG
Lancet; 2023 Oct; 402(10412):1541-1551. PubMed ID: 37738999
[TBL] [Abstract][Full Text] [Related]
31. Current management of generalized pustular psoriasis.
Kodali N; Blanchard I; Kunamneni S; Lebwohl MG
Exp Dermatol; 2023 Aug; 32(8):1204-1218. PubMed ID: 36779681
[TBL] [Abstract][Full Text] [Related]
32. Pathophysiology of generalized pustular psoriasis.
Young KZ; Sarkar MK; Gudjonsson JE
Exp Dermatol; 2023 Aug; 32(8):1194-1203. PubMed ID: 36779688
[TBL] [Abstract][Full Text] [Related]
33. Review of treatments for generalized pustular psoriasis.
Kearns DG; Chat VS; Zang PD; Han G; Wu JJ
J Dermatolog Treat; 2021 Aug; 32(5):492-494. PubMed ID: 31697211
[TBL] [Abstract][Full Text] [Related]
34. Rapid and sustained response to spesolimab in five Chinese patients with generalized pustular psoriasis.
Ran D; Yang B; Sun L; Wang N; Qu P; Liu J; Pan F; Wang G; Wu W; Zhang Z; Shi Z; Yang Q; Liu H; Zhang F
Clin Exp Dermatol; 2023 Jul; 48(7):803-805. PubMed ID: 36994823
[No Abstract] [Full Text] [Related]
35. Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation.
Armstrong AW; Elston CA; Elewski BE; Ferris LK; Gottlieb AB; Lebwohl MG;
J Am Acad Dermatol; 2024 Apr; 90(4):727-730. PubMed ID: 37838256
[No Abstract] [Full Text] [Related]
36. A review of disease burden and clinical management for generalized pustular psoriasis in China.
Lu J; Shi Y
Expert Rev Clin Immunol; 2022 Oct; 18(10):1023-1032. PubMed ID: 36040447
[TBL] [Abstract][Full Text] [Related]
37. Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study.
Burden AD; Bissonnette R; Navarini AA; Murakami M; Morita A; Haeufel T; Ye B; Baehner F; Terui T
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2279-2297. PubMed ID: 37731086
[TBL] [Abstract][Full Text] [Related]
38. Clinical advances in biological therapy for generalized pustular psoriasis: a review.
Hsieh CY; Tsai TF
Expert Opin Biol Ther; 2024; 24(1-2):37-50. PubMed ID: 38247394
[TBL] [Abstract][Full Text] [Related]
39. Spesolimab: a comprehensive review on the anti-IL-36 receptor antibody in dermatology.
Palaniappan V; Gopinath H; Murthy AB; Radhakrishnan S; Karthikeyan K
Int J Dermatol; 2024 Jan; 63(1):88-93. PubMed ID: 38031264
[TBL] [Abstract][Full Text] [Related]
40. A Case of Old Age-Onset Generalized Pustular Psoriasis with a Deficiency of IL-36RN (DITRA) Treated by Granulocyte and Monocyte Apheresis.
Tominaga C; Yamamoto M; Imai Y; Yamanishi K
Case Rep Dermatol; 2015; 7(1):29-35. PubMed ID: 25848350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
